Is there a role for safinamide in atypical parkinsonian syndromes?
Objective: To search for possible benefits of safinamide in atypical parkinsonism. Background: Safinamide is a selective reversible monoamine oxidase-B inhibitor with both dopaminergic and glutamatergic…Neurophysiological and Clinical Effects of Low-intensity Transcranial Ultrasound of the Motor Cortex in Parkinson’s Disease
Objective: Evaluate the neurophysiological and clinical effects of transcranial ultrasound stimulation (TUS) of motor cortex (M1) in PD patients. Background: Low-intensity TUS is a novel,…Longitudinal Program to Prevent PD (LoPP-PD): Multimodal Risk Stratification Informs Personalized Intervention
Objective: Longitudinal evaluation of personalized intervention strategies informed by detailed clinical and laboratory biomarker analysis to reduce relative risk of Parkinson’s disease in first degree…Antidyskinetic Effects of CaV1.3 Calcium Channel Gene Silencing in Aged Male and Female Parkinsonian Macaques
Objective: To determine whether striatal CaV1.3 gene silencing ameliorates levodopa-induced dyskinesias (LID) in the preclinical gold-standard non-human primate (NHP) model without altering levodopa’s antiparkinsonian benefit.…Silencing dopamine neurons during sleep slows disease progression in parkinsonian mice
Objective: To develop a treatment to stop or slow the progression of Parkinson's disease. Background: Parkinson’s disease (PD) is believed to be caused by the…Striatal Blood brain barrier opening in Parkinson´s disease
Objective: To test safety and feasibility of repeated low-intensity focused ultrasound (FUS) blood brain barrier opening (BBB) in the striatum of Parkinson’s disease (PD) patients.…Use of alternative healing for Parkinson’s disease in Kenya
Objective: To explore the experience of alternative healing practices by people with Parkinson’s disease in Kenya. Background: As a neurodegenerative condition, Parkinson’s disease (PD) requires…Phase 1/2 Open-label Dose Evaluation Study of AXO-Lenti-PD Gene Therapy for Parkinson’s Disease: Efficacy, Safety, and Tolerability Data from the Second Cohort at 6 Months
Objective: Results from cohort 2 in the Phase 1/2 SUNRISE-PD study (NCT03720418) at 6 months (6M) post administration of AXO-Lenti-PD (ALPD) gene therapy are presented.…Overcoming clinical research challenges during a pandemic: selection and implementation of digital phenotyping solutions in a natural history study of G2019S LRRK2 Parkinson’s disease.
Objective: To identify candidate wearable devices or digital solutions suitable for conducting the Timed Up and Go (TUG) test and evaluate real-world performance remotely during…PHYSICAL ACTIVITY AT HOME IS ABLE TO REDUCE THE WORSENING IN QUALITY OF LIFE IN PARKINSON’S DISEASE DURING COVID-19 PANDEMIC
Objective: To compare the effects of physical activity (PA) at home with and without remote supervision on the motor and non-motor aspects of daily life…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 12
- Next Page »